Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study (vol 15, pg 1503, 2014)

Kumar S. K.; Berdeja J. G.; Niesvizky R.

首页> 外文期刊>The lancet oncology >Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study (vol 15, pg 1503, 2014)

【24h】

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study (vol 15, pg 1503, 2014)

机译：Ixazomib的安全性和耐受性，口服蛋白酶体抑制剂与先前未经处理的多发性骨髓瘤患者的血红华和地塞米松组合：开放标签阶段1/2研究（Vol 15，PG 1503,2014）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2019年第7期|共1页
作者
Kumar S. K.; Berdeja J. G.; Niesvizky R.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献

1. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study (vol 15, pg 1503, 2014) [J] . Kumar S. K., Berdeja J. G., Niesvizky R. The lancet oncology . 2019,第7期

机译：Ixazomib的安全性和耐受性，口服蛋白酶体抑制剂与先前未经处理的多发性骨髓瘤患者的血红华和地塞米松组合：开放标签阶段1/2研究（Vol 15，PG 1503,2014）
2. Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies [J] . Fu Weijun, Lu Jin, Jin Jie, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：口腔Ixazomib的整体存活（OS）益处与Lenalalomide和Dexamethasone（IRD）与亚洲患者（PTS）组合的亚洲患者（PTS）的益处（PTS）组合，具有复发和/或难治性多骨髓瘤（RRMM）：汇总 - 从陀螺俱乐部分析 - MM1和中国延续研究
3. Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyeLome (IFM) [J] . Moreau Philippe, Hulin Cyrille, Caillot Denis, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：新诊断的多发性骨髓瘤（NDMM）患者自体干细胞移植（ASCT）前后依沙佐米-来那度胺-地塞米松（IRd）的联合治疗，伊沙佐米的维持：法语国家杜米勒美氏病（IFM）组的第二阶段研究
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1 [O] . María-Victoria Mateos, Tamas Masszi, Norbert Grzasko, 2017

机译：在TOURMALINE-MM1复发/难治性多发性骨髓瘤患者中既往治疗对口服艾达唑仑-来那度胺-地塞米松与安慰剂-来那度胺-地塞米松的疗效和安全性的影响
6. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor [O] . Samantha Hinsley, Katrina Walker, Debbie Sherratt, 2020

机译：MUK 8方案：环磷酰胺和地塞米松的随机期II试验与Ixazomib，复发或难治性多发性骨髓瘤（RRMM）患者与亚马亚度胺，Lenalidomide和蛋白酶体抑制剂进行处理后复发

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study (vol 15, pg 1503, 2014)

著录项

相似文献

相关主题

期刊订阅